Amal Therapeutics announces an exclusive patent license agreement with the University of Minnesota
28.10.2015
Amal Therapeutics SA ("Amal”), a Geneva based biotechnology company active in cancer immunotherapy announced today the signature of an exclusive patent license agreement with the University of Minnesota for the use of a novel peptide with potent immunostimulatory properties.
 The venture leaders USA team of 2012 with Madiha Derouazi (second left, first row).
|
 |
This novel peptide was discovered by the University of Minnesota’s Dr. John Ohlfest and Dr. Mike Olin seeking to enhance the effects of immunotherapy cancer vaccines. It was shown to have a unique mechanism of action, which led to significant activity over other adjuvants in pre-clinical testing.
"The signature of this exclusive license agreement is an important milestone in the Amal development process. It consolidates our IP position and gives Amal the freedom to operate to further develop its Kisima technology platform” said Madiha Derouazi, Amal Therapeutics CEO.
About Amal Therapeutics SA
Amal Therapeutics SA is a privately held Swiss/German biotech start-up company and spin-off from the University of Geneva. Amal Therapeutics was incorporated in September 2012. Amal uses Kisima, its proprietary technology platform, to develop and progress therapeutic vaccines in oncology. Amal Therapeutics is a Venture Kick alumni and a venture leader USA 2012.
Amal reaches milestone after milestone. They jumped this year from rank Nr. 98 in 2014 to Nr. 34 in the TOP100. Over the past year, major investors have piled into the Geneva-based startup and an experienced pharmaceutical manager took over as president of the supervisory board. This year, Amal also made headlines on the technological/medical side of things. Cancer Research published Amal's study results in June. Cancer Research is no run-of-the-mill journal, but the most-cited one. Amal CEO Madiha Derouazihad this to say: “Our research results represent the proof of concept and demonstrate the strengths of our technology platform for the development of safe and effective vaccines against cancer.”
About the University of Minnesota
Founded in 1851, the University of Minnesota is ranked among the nation's top public research universities. As a land-grant institution, the U of M is committed to engaging Minnesota, national and global communities to advance interdisciplinary knowledge; enhance students' academic, civic, career, social and personal development; and apply intellectual and human capital to serve the public good.